Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AOTI, Inc. ( (GB:AOTI) ) has shared an update.
AOTI, Inc. has announced the release of its interim results for the first half of 2025, scheduled for September 22, 2025. The company will host meetings for analysts and investors to discuss these results, with opportunities for stakeholders to engage through presentations and Q&A sessions. This announcement underscores AOTI’s commitment to transparency and stakeholder engagement, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (GB:AOTI) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on AOTI, Inc. stock, see the GB:AOTI Stock Forecast page.
Spark’s Take on GB:AOTI Stock
According to Spark, TipRanks’ AI Analyst, GB:AOTI is a Neutral.
The overall score reflects a mix of positive corporate events and challenges in financial performance and valuation. Insider confidence and strategic milestones are offset by bearish technical signals and lack of profitability.
To see Spark’s full report on GB:AOTI stock, click here.
More about AOTI, Inc.
AOTI, Inc., founded in 2006 and based in Oceanside, California, US, and Galway, Ireland, specializes in innovative medical technology solutions for severe and chronic wounds. Its flagship product, the patented non-invasive Topical Wound Oxygen (TWO2®) therapy, has shown significant efficacy in reducing the recurrence of Diabetic Foot Ulcers (DFUs), hospitalizations, and amputations. The therapy is globally recognized and approved by various health authorities, including the US FDA and European CE Mark.
Average Trading Volume: 333,182
Technical Sentiment Signal: Sell
Current Market Cap: £58.5M
See more data about AOTI stock on TipRanks’ Stock Analysis page.